Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 668,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,243.33 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.14% of total voting rights).
- Shares in Issue: 5,187,015,382 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 668,000 shares purchased on December 19, 2008. This transaction increased the proportion of Treasury shares held by the Company to 9.14% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership notifications.
Investor Verification Checklist
- Verify the total number of shares in issue (5,187,015,382) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on voting rights (9.14%).
- Note that the 668,000 shares purchased were cancelled, permanently reducing the authorized share count.